Skip to main content
SpringerLink
Log in

Cancer-Related Gene Therapy Clinical Trials

  • Chapter
Cancer Gene Therapy

Part of the book series: Contemporary Cancer Research ((CCR))

Abstract

Gene therapy represents a strategy using transfer of genetic information to modify a population of target cells for therapeutic purposes. The transferred genetic material has typically included double-stranded deoxyribonucleic acid (DNA), but occasionally single-stranded DNA and even ribonucleic acid (RNA). Gene therapy represents one of the many novel “targeted” antineoplastic treatment approaches with the goal to inhibit the growth of tumor cells and spare normal cells. The use of gene therapy relevant to cancer treatment includes the in vivo genetic modification of tumors or the tumor-bearing host, as well as the ex vivo genetic manipulation of cell populations, which are then administered to the tumor-bearing host.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nottage, M. and Siu, L. L. (2002) Principles of clinical trial design. J. Clin. Oncol. 20(18, Suppl.), 42s–46s.

    PubMed  Google Scholar 

  2. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205–216.

    Article  PubMed  CAS  Google Scholar 

  3. Shand, N., Weber, F., Mariani, L., et al. (1999) A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. 10, 2325–2335.

    Article  PubMed  CAS  Google Scholar 

  4. Swisher, S. G., Roth, J. A., Nemunaitis, J., et al. (1999) Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 91, 763–771.

    Article  PubMed  CAS  Google Scholar 

  5. Osanto, S., Schiphorst, P. P., Weijl, N. I., et al. (2000) Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum. Gene Ther. 11, 739–750.

    Article  PubMed  CAS  Google Scholar 

  6. Jansen, B. and Zangemeister-Wittke, U. (2002) Antisense therapy for cancer—the time of truth. Lancet Oncol. 3, 672–683.

    Article  PubMed  CAS  Google Scholar 

  7. Harvey, B. G., Maroni, J., O’Donoghue, K. A., et al. (2002) Safety of local delivery of low-and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum. Gene Ther. 13, 15–63.

    Article  PubMed  CAS  Google Scholar 

  8. Vile, R. G. and Russell, S. J. (1995) Retroviruses as vectors. Br. Med. Bull. 51, 12–30.

    PubMed  CAS  Google Scholar 

  9. Marshall, E. (1999) Clinical trials: gene therapy death prompts review of adenovirus vector. Science 286, 2244–2245.

    Article  PubMed  CAS  Google Scholar 

  10. Verma, I. M. (2002) Success and setback: another adverse event. Mol. Ther. 6, 565–566.

    Article  PubMed  CAS  Google Scholar 

  11. Reid, T., Warren, R., and Kirn, D. (2002) Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 9, 979–986.

    Article  PubMed  CAS  Google Scholar 

  12. Saygili, U., Guclu, S., Uslu, T., Erten, O., and Dogan, E. (2002) The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. Int. J. Gynecol. Cancer 12, 438–442.

    Article  PubMed  CAS  Google Scholar 

  13. Small, E. J. and Roach, M. 3rd. (2002) Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin. Oncol. 29, 264–273.

    Article  PubMed  CAS  Google Scholar 

  14. Freytag, S. O., Khil, M., Stricker, H., et al. (2002) Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62, 4968–4976.

    PubMed  CAS  Google Scholar 

  15. Habib, N. A., Sarraf, C. E., Mitry, R. R., et al. (2001) E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Ther. 12, 219–226.

    Article  PubMed  CAS  Google Scholar 

  16. Cormier, J. N., Salgaller, M. L., Prevette, T., et al. (1997) Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/melan A. Cancer J. 3, 37–44.

    CAS  Google Scholar 

  17. Simon, R. (1989) Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10, 1–10.

    Article  CAS  Google Scholar 

  18. Korst, R. J., Ailawadi, M., Lee, J. M., et al. (2001) Adenovirus gene transfer vectors inhibit lymphatic tumor metastasis independent of a therapeutic transgene. Hum. Gene Ther. 12, 1639–1649.

    Article  PubMed  CAS  Google Scholar 

  19. Kopec, J. A., Abrahamowicz, M., and Esdaile, J. M. (1993) Randomized discontinuation trials: utility and efficiency. J. Clin. Epidemiol. 46, 959–971.

    Article  PubMed  CAS  Google Scholar 

  20. Schmidt-Wolf, I. G., Finke, S., Trojaneck, B., et al. (1999) Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br. J. Cancer 81, 1009–1016.

    Article  PubMed  CAS  Google Scholar 

  21. Tan, Y., Xu, M., Wang, W., et al. (1996) IL-2 gene therapy of advanced lung cancer patients. Anticancer Res. 16, 1993–1998.

    PubMed  CAS  Google Scholar 

  22. Rosenberg, S. A., Aebersold, P., Cornetta, K., et al. (1990) Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570–578.

    Article  PubMed  CAS  Google Scholar 

  23. Merrouche, Y., Negrier, S., Bain, C., et al. (1995) Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J. Clin. Oncol. 13, 410–418.

    PubMed  CAS  Google Scholar 

  24. Batliwalla, F. M., Bateman, B. A., Serrano, D., et al. (1998) A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol. Med. 4, 783–794.

    PubMed  CAS  Google Scholar 

  25. Nabel, G. J., Nabel, E. G., Yang, Z. Y., et al. (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA 90, 11,307–11,311.

    Article  PubMed  CAS  Google Scholar 

  26. Atkins, M. B., Lotze, M. T., Dutcher, J. P., et al. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105–2116.

    PubMed  CAS  Google Scholar 

  27. Vial, T. and Descotes, J. (1994) Clinical toxicity of the interferons. Drug Saf. 10, 115–150.

    PubMed  CAS  Google Scholar 

  28. Galanis, E., Hersh, E. M., Stopeck, A. T., et al. (1999) Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J. Clin. Oncol. 17, 3313–3323.

    PubMed  CAS  Google Scholar 

  29. Nemunaitis, J., Bohart, C., Fong, T., et al. (1998) Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther. 5, 292–300.

    PubMed  CAS  Google Scholar 

  30. Arienti, F., Belli, F., Napolitano, F., et al. (1999) Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 10, 2907–2916.

    Article  PubMed  CAS  Google Scholar 

  31. Mastrangelo, M. J., Maguire, H. C. Jr., Eisenlohr, L. C., et al. (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6, 409–422.

    Article  PubMed  CAS  Google Scholar 

  32. Kang, W. K., Park, C., Yoon, H. L., et al. (2001) Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum. Gene Ther. 12, 671–684.

    Article  PubMed  CAS  Google Scholar 

  33. Moller, P., Sun, Y., Dorbic, T., et al. (1998) Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br. J. Cancer 77, 1907–1916.

    PubMed  CAS  Google Scholar 

  34. Wierda, W. G., Cantwell, M. J., Woods, S. J., Rassenti, L. Z., Prussak, C. E., and Kipps, T. J. (2000) CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96, 2917–2924.

    PubMed  CAS  Google Scholar 

  35. Antonia, S. J., Seigne, J., Diaz, J., et al. (2002) Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. 167, 1995–2000.

    Article  PubMed  CAS  Google Scholar 

  36. Eder, J. P., Kantoff, P. W., Roper, K., et al. (2000) A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6, 1632–1638.

    PubMed  CAS  Google Scholar 

  37. Conry, R. M., Khazaeli, M. B., Saleh, M. N., et al. (1999) Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal vs subcutaneous administration. Clin. Cancer Res. 5, 2330–2337.

    PubMed  CAS  Google Scholar 

  38. Scholl, S. M., Balloul, J. M., Le Goc, G., et al. (2000) Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother. 23, 570–580.

    Article  PubMed  CAS  Google Scholar 

  39. Rosenberg, S. A., Zhai, Y., Yang, J. C., et al. (1998) Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90, 1894–1900.

    Article  PubMed  CAS  Google Scholar 

  40. Nair, S. K., Morse, M., Boczkowski, D., et al. (2002) Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 235, 540–549.

    Article  PubMed  Google Scholar 

  41. Yazawa, K., Fisher, W. E., and Brunicardi, F. C. (2002) Current progress in suicide gene therapy for cancer. World J. Surg. 26, 783–789.

    Article  PubMed  Google Scholar 

  42. Miles, B. J., Shalev, M., Aguilar-Cordova, E., et al. (2001) Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum. Gene Ther. 12, 1955–1967.

    Article  PubMed  CAS  Google Scholar 

  43. Sterman, D. H., Treat, J., Litzky, L. A., et al. (1998) Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 9, 1083–1092.

    Article  PubMed  CAS  Google Scholar 

  44. Klatzmann, D., Valery, C. A., Bensimon, G., et al. (1998) A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther. 9, 2595–2604.

    Article  PubMed  CAS  Google Scholar 

  45. Sandmair, A. M., Loimas, S., Puranen, P., et al. (2000) Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. 11, 2197–2205.

    Article  PubMed  CAS  Google Scholar 

  46. Rainov, N. G. (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11, 2389–2401.

    Article  PubMed  CAS  Google Scholar 

  47. Pandha, H. S., Martin, L. A., Rigg, A., et al. (1999) Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin. Oncol. 17, 2180–2189.

    PubMed  CAS  Google Scholar 

  48. Chung-Faye, G., Palmer, D., Anderson, D., et al. (2001) Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 7, 2662–2668.

    PubMed  CAS  Google Scholar 

  49. Lohr, M., Hoffmeyer, A., Kroger, J., et al. (2001) Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 357, 1591–1592.

    Article  PubMed  CAS  Google Scholar 

  50. Thames, H. D., Petersen, C., Petersen, S., Nieder, C., and Baumann, M. (2002) Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data. Strahlenther Onkol. 178, 411–421.

    Article  PubMed  Google Scholar 

  51. Roth, J. A., Nguyen, D., Lawrence, D. D., et al. (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2, 985–991.

    Article  PubMed  CAS  Google Scholar 

  52. Schuler, M., Rochlitz, C., Horowitz, J. A., et al. (1998) A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gene Ther. 9, 2075–2082.

    PubMed  CAS  Google Scholar 

  53. Tait, D. L., Obermiller, P. S., Redlin-Frazier, S., et al. (1997) A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin. Cancer Res. 3, 1959–1968.

    PubMed  CAS  Google Scholar 

  54. Tait, D. L., Obermiller, P. S., Hatmaker, A. R., Redlin-Frazier, S., and Holt, J. T. (1999) Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stability. Clin. Cancer Res. 5, 1708–1714.

    PubMed  CAS  Google Scholar 

  55. Biederer, C., Ries, S., Brandts, C. H., and McCormick, F. (2002) Replication-selective viruses for cancer therapy. J. Mol. Med. 80, 163–175.

    Article  PubMed  CAS  Google Scholar 

  56. Habib, N. A., Sarraf, C. E., Mitry, R. R., et al. (2001) E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Ther. 12, 219–226.

    Article  PubMed  CAS  Google Scholar 

  57. Vasey, P. A., Shulman, L. N., Campos, S., et al. (2002) Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 20, 1562–1569.

    Article  PubMed  CAS  Google Scholar 

  58. Nemunaitis, J., Khuri, F., Ganly, I., et al. (2001) Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289–298.

    PubMed  CAS  Google Scholar 

  59. Markert, J. M., Medlock, M. D., Rabkin, S. D., et al. (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7, 867–874.

    Article  PubMed  CAS  Google Scholar 

  60. Rampling, R., Cruickshank, G., Papanastassiou, V., et al. (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 859–866.

    Article  PubMed  CAS  Google Scholar 

  61. Pecora, A. L., Rizvi, N., Cohen, G. I., et al. (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20, 2251–2266.

    Article  PubMed  CAS  Google Scholar 

  62. Bishop, M. R., Iversen, P. L., Bayever, E., et al. (1996) Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. 14, 1320–1326.

    PubMed  CAS  Google Scholar 

  63. Chen, H. X., Marshall, J. L., Ness, E., et al. (2000) A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by 2-hour infusions in patients with refractory solid tumors. Clin. Cancer Res. 6, 1259–1266.

    PubMed  CAS  Google Scholar 

  64. Luger, S. M., O’Brien, S. G., Ratajczak, J., et al. (2002) Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 99, 1150–1158.

    Article  PubMed  CAS  Google Scholar 

  65. Andrews, D. W., Resnicoff, M., Flanders, A. E., et al. (2001) Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J. Clin. Oncol. 19, 2189–2200.

    PubMed  CAS  Google Scholar 

  66. Cunningham, C. C., Holmlund, J. T., Geary, R. S., et al. (2001) A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 92, 1265–1271.

    Article  PubMed  CAS  Google Scholar 

  67. Coudert, B., Anthoney, A., Fiedler, W., et al. (2001) Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur. J. Cancer 37, 2194–2198.

    Article  PubMed  CAS  Google Scholar 

  68. Jansen, B., Wacheck, V., Heere-Ress, E., et al. (2000) Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728–1733.

    Article  PubMed  CAS  Google Scholar 

  69. Yuen, A. R., Halsey, J., Fisher, G. A., et al. (1999) Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. 5, 3357–3363.

    PubMed  CAS  Google Scholar 

  70. Bishop, M. R., Jackson, J. D., Tarantolo, S. R., et al. (1997) Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. J. Hematother. 6, 441–446.

    PubMed  CAS  Google Scholar 

  71. Waters, J. S., Webb, A., Cunningham, D., et al. (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma. J. Clin. Oncol. 18, 1812–1823.

    PubMed  CAS  Google Scholar 

  72. Devereux, S., Corney, C., Macdonald, C., et al. (1998) Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood stem cell transplantation for lymphoma. Gene Ther. 5, 403–408.

    Article  PubMed  CAS  Google Scholar 

  73. Hesdorffer, C., Ayello, J., Ward, M., et al. (1998) Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J. Clin. Oncol. 16, 165–172.

    PubMed  CAS  Google Scholar 

  74. Tiberghien, P., Ferrand, C., Lioure, B., et al. (2001) Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97, 63–72.

    Article  PubMed  CAS  Google Scholar 

  75. Sang, N., Caro, J., and Giordano, A. (2002) Adenoviral E1A: everlasting tool, versatile applications, continuous contributions and new hypotheses. Front. Biosci. 7, d407–d413.

    Article  PubMed  CAS  Google Scholar 

  76. Hortobagyi, G. N., Ueno, N. T., Xia, W., et al. (2001) Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J. Clin. Oncol. 19, 3422–3433.

    PubMed  CAS  Google Scholar 

  77. Yoo, G. H., Hung, M. C., Lopez-Berestein, G., et al. (2001) Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin. Cancer Res. 7, 1237–1245.

    PubMed  CAS  Google Scholar 

  78. Villaret, D., Glisson, B., Kenady, D., et al. (2002) A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck 24, 661–669.

    Article  PubMed  Google Scholar 

  79. Alvarez, R. D., Barnes, M. N., Gomez-Navarro, J., et al. (2000) A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin. Cancer Res. 6, 3081–3087.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Weill Medical College of Cornell University, New York, NY

    Robert J. Korst

  2. Division of Thoracic Surgery, Department of Genetic Medicine, Weill Medical College of Cornell University, New York, NY

    Robert J. Korst

  3. Department of Genetic Medicine, Weill Medical College of Cornell University, New York, NY

    Ronald G. Crystal

  4. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Medical College of Cornell University, New York, NY

    Ronald G. Crystal

Authors
  1. Robert J. Korst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald G. Crystal
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

    David T. Curiel MD, PhD  & Joanne T. Douglas PhD  & 

  2. Division of Human Gene Therapy, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL

    David T. Curiel MD, PhD  & Joanne T. Douglas PhD  & 

  3. Division of Human Gene Therapy, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL

    David T. Curiel MD, PhD  & Joanne T. Douglas PhD  & 

  4. Division of Human Gene Therapy, Department of Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL

    David T. Curiel MD, PhD  & Joanne T. Douglas PhD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Korst, R.J., Crystal, R.G. (2005). Cancer-Related Gene Therapy Clinical Trials. In: Curiel, D.T., Douglas, J.T. (eds) Cancer Gene Therapy. Contemporary Cancer Research. Humana Press. https://doi.org/10.1007/978-1-59259-785-7_28

Download citation

Publish with us

Policies and ethics

Search

Navigation